Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I ...

Now, all eyes are set on the FDA-approved drug Ruxolitinib, manufactured by Incyte Pharmaceuticals, which is the first drug that can restore pigment in patients with nonsegmental vitiligo.

Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

Incyte INCY announced positive results from two late-stage studies evaluating the safety and efficacy of its twice-daily ...

HONG KONG SAR - Media OutReach Newswire - 27 March 2025 - At today's press conference, members of the education expert panel on vitiligo, including Dr Johnny Chan Chun-yin, ...

Patients with vitiligo who received long-term NBUVB phototherapy vs no phototherapy were associated with reduced risks for cardiometabolic diseases.

ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...

However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...

Significantly more patients who applied ruxolitinib cream 1.5% versus vehicle ... compared to its use for atopic dermatitis and vitiligo. Price Action: INCY stock is up 0.92% at $71.44 at the ...

non-segmental vitiligo with genital involvement, hidradenitis suppurativa, lichen planus, and lichen sclerosus. Two Phase III trials, TRuE-PN1 and TRuE-PN2, assessing ruxolitinib cream for prurigo ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first FDA ...

OPZELURA Continues to Revolutionize the Dermatology Market with Strong Market Uptake | DelveInsight OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in ...